

Hanping Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8875692/publications.pdf>

Version: 2024-02-01

52
papers

1,015
citations

623734

14
h-index

477307

29
g-index

65
all docs

65
docs citations

65
times ranked

2126
citing authors

#	ARTICLE	IF	CITATIONS
1	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1059-1066.	1.9	2
2	Conversion therapy of stage IVb unresectable gallbladder carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 335-337.	1.5	2
3	Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with) Tj ETQq1 1 0.784314 rgBT /Overlock 1 small cell lung cancer: A phase II study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8573-8573.	1.6	0
4	Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study. <i>Cancer Medicine</i> , 2021, 10, 188-198.	2.8	11
5	Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 357-363.	1.9	15
6	Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy. <i>BMC Medicine</i> , 2021, 19, 154.	5.5	32
7	Fasciitis induced by sintilimab in a patient with recurrent hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2021, 155, 296-298.	2.8	1
8	Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2021, 156, 122-124.	2.8	7
9	A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer. <i>Pharmacological Research</i> , 2021, 174, 105931.	7.1	7
10	Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 728253.	2.8	1
11	Management of immune checkpoint inhibitor-related dermatologic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 488-492.	1.9	17
12	Management of immune checkpoint inhibitor-related rheumatic adverse events. <i>Thoracic Cancer</i> , 2020, 11, 198-202.	1.9	2
13	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. <i>Thoracic Cancer</i> , 2020, 11, 191-197.	1.9	52
14	Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. <i>Thoracic Cancer</i> , 2020, 11, 475-480.	1.9	9
15	Use of glucocorticoids in the management of immunotherapy-related adverse effects. <i>Thoracic Cancer</i> , 2020, 11, 3047-3052.	1.9	13
16	<p>NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 5975-5985.	1.9	7
17	Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events. <i>Thoracic Cancer</i> , 2020, 11, 2077-2086.	1.9	1
18	A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096584.	3.2	7

#	ARTICLE	IF	CITATIONS
19	Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum+pemetrexed: The first report of two cases. <i>Thoracic Cancer</i> , 2020, 11, 2339-2342.	1.9	3
20	Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1216-1223.	1.9	5
21	Tocilizumab for Fulminant Programmed Death 1 Inhibitor-associated Myocarditis. <i>Journal of Thoracic Oncology</i> , 2020, 15, e31-e32.	1.1	13
22	Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. <i>Thoracic Cancer</i> , 2020, 11, 829-834.	1.9	5
23	Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. <i>Thoracic Cancer</i> , 2020, 11, 799-804.	1.9	24
24	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	1.9	19
25	Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. <i>Thoracic Cancer</i> , 2020, 11, 1099-1104.	1.9	5
26	Risk of COVID-19 for patients with cancer. <i>Lancet Oncology</i> , The, 2020, 21, e181.	10.7	364
27	Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. <i>Thoracic Cancer</i> , 2020, 11, 805-809.	1.9	8
28	Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. <i>Thoracic Cancer</i> , 2020, 11, 594-602.	1.9	14
29	Management of immune checkpoint inhibitor-related adverse events: A review of case reports. <i>Thoracic Cancer</i> , 2020, 11, 498-504.	1.9	10
30	Histologic transformation of lung cancer during pembrolizumab therapy: A case report. <i>Thoracic Cancer</i> , 2020, 11, 793-796.	1.9	10
31	Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. <i>Thoracic Cancer</i> , 2020, 11, 1746-1751.	1.9	11
32	Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 1647-1654.	1.9	18
33	Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. <i>Thoracic Cancer</i> , 2020, 11, 1621-1632.	1.9	44
34	Opportunistic infections complicating immunotherapy for non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 1689-1694.	1.9	11
35	A validated ultra-HPLC-MS/MS method for determination of honokiol in human plasma and its application to a clinical pharmacokinetic study. <i>Bioanalysis</i> , 2019, 11, 1085-1098.	1.5	5
36	Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 5545-5549.	2.0	4

#	ARTICLE	IF	CITATIONS
37	Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, e141-e143.	1.1	3
38	Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. <i>Thoracic Cancer</i> , 2019, 10, 551-556.	1.9	42
39	Evaluation of Lung Cancer and Neuroendocrine Neoplasm in a Single Scan by Targeting Both Somatostatin Receptor and Integrin $\alpha v \beta 3$. <i>Clinical Nuclear Medicine</i> , 2019, 44, 687-694.	1.3	14
40	Lack of a pulmonary vein causing unilateral interlobular septal thickening. <i>Thorax</i> , 2018, 73, 199-200.	5.6	1
41	Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7513-7519.	2.0	6
42	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018, 125, 142-149.	2.0	34
43	Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 32-37.	2.0	32
44	Penetration of the blood-brain barrier by avitinib and its control of intra/extra-cranial disease in non-small cell lung cancer harboring the T790M mutation. <i>Lung Cancer</i> , 2018, 122, 1-6.	2.0	17
45	Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. <i>Thoracic Cancer</i> , 2018, 9, 1056-1061.	1.9	7
46	Development of an UPLC-MS/MS method for quantification of Avitinib (AC0010) and its five metabolites in human cerebrospinal fluid: Application to a study of the blood-brain barrier penetration rate of non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 205-214.	2.8	13
47	Clinical and diagnostic features of angiosarcoma with pulmonary metastases. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Overlock</i>	1.0	21
48	The ability of avitinib to penetrate the blood brain barrier and its control of intra-/extra- cranial disease in patients of non-small cell lung cancer (NSCLC) harboring EGFR T790M mutation.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20613-e20613.	1.6	7
49	Phase Ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20642-e20642.	1.6	0
50	Diffuse Cystic Lung Diseases: Diagnostic Considerations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 457-467.	2.1	24
51	Biopsy-proven IgG4-related lung disease. <i>BMC Pulmonary Medicine</i> , 2016, 16, 20.	2.0	26
52	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19070-e19070.	1.6	0